---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-23-000109"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2023-09-19T23:59:59+00:00"
generated_at: "2026-06-10T14:22:08.747582+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Exelixis finalizes separation with former CMO Vicki Goodman, consulting through Dec 2023

## Summary
- Dr. Goodman concluded service as EVP Product Development & CMO effective August 23, 2023.
- Separation agreement provides severance payments and benefits under company's Change in Control and Severance Benefit Plan, payable in lump sum.
- Consulting agreement for up to 4 months (Sept 1 to Dec 31, 2023) with monthly fee of $20,000.
- Consulting may be terminated by either party with 5 business days' notice.

## SEC filing metadata
- accession: 0000939767-23-000109
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2023-09-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976723000109/0000939767-23-000109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976723000109/exel-20230913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-23-000109
- JSON: https://secwatch.observer/filing/0000939767-23-000109.json
- Plain text: https://secwatch.observer/filing/0000939767-23-000109.txt

## Key facts
- Executive change
  Vicki L. Goodman departed as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer at EXELIXIS, INC..
  - Action: concluded
  - Role: Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
  source text: Vicki L. Goodman, M.D., concluded her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of the Company, effective as of August 23, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/939767/000093976723000109/0000939767-23-000109-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.